The Role of Radiotherapy for Patients with Unresectable Locally Advanced Breast Cancer following Neoadjuvant Systemic Therapy

Table 6

Univariate and multivariate analyses of patient clinical and treatment-related factors for LRPFS and PFS.

Parameters	LRPFS			PFS
	1-year LRPFS (%)			1-year PFS (%)
		UVA	MVA		UVA	MVA
Age		0.033	0.222		0.272	0.576
≤40	94.7			66.7
>40	72.5			54.8
Menopausal status		0.057	0.465		0.121	0.428
Pre-menopause	84.1			60.3
Post-menopause	73.0			54.0
Pre-treatment TNM stage		0.261	0.058		0.315	0.182
IIIA + IIIB	79.9			57.6
IIIC + IV	79.0			57.8
Molecular subtype		0.006	0.268		0.003	0.061
Luminal A/B + HER2-overexpressed	91.4			74.0
Triple-negative	62.4			37.6
Boost		0.487	0.975		0.462	0.734
No	68.0			54.7
Yes	85.3			60.3
Concurrent chemotherapy		0.533	0.618		0.317	0.403
No	82.5			58.4
Yes	76.4			57.8
cCR		<0.001	<0.001		0.001	0.002
Non-any cCR	58.6			37.5
Any cCR	92.2			72.1

LRPFS = locoregional progression-free survival; PFS = progression-free survival; cCR = clinical complete response; UVA = univariate analysis; MVA = multivariate analysis.